Form 8-K

8-K — Sensus Healthcare, Inc.

Accession: 0001753926-26-001479

Filed: 2026-08-13

Period: 2026-08-13

CIK: 0001494891

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — g085863_8k.htm (Primary)

EX-99.1 — EXHIBIT 99-1 (g085863_ex99-1.htm)

GRAPHIC (img001_v1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: g085863_8k.htm · Sequence: 1

false

0001494891

false

0001494891

2026-08-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 13, 2026

SENSUS

HEALTHCARE, INC.

(Exact name of registrant as specified in

its charter)

Delaware

001-37714

27-1647271

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

851

Broken Sound Pkwy., NW # 215, Boca Raton, Florida

33487

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (561) 922-5808

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the

Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

(see General Instruction A.2. below):

[ ] Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

SRTS

Nasdaq

Stock Market, LLC

Indicate by check mark whether the registrant is an emerging

growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate

by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial

accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

SENSUS HEALTHCARE, INC.

FORM 8-K

CURRENT REPORT

Item 2.02 Results of Operation and Financial Condition

On August 13, 2026, Sensus Healthcare, Inc. announced via press

release its financial results for the second quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current

Report on Form 8-K and incorporated herein by reference.

The press release makes reference to certain non-GAAP financial

measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.

The information furnished under Item 2.02, including in Exhibit

99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be

deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific

reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release, dated August 13, 2026.

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

SENSUS HEALTHCARE, INC.

Date: August 13, 2026 By: /s/ Javier Rampolla

Javier Rampolla

Chief Financial Officer

EXHIBIT INDEX

Exhibit

Number

Description

99.1

Press Release, dated August 13, 2026.

EX-99.1 — EXHIBIT 99-1

EX-99.1

Filename: g085863_ex99-1.htm · Sequence: 2

Exhibit

99.1

Sensus

Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Commercial

Momentum Builds Following CPT Code Implementation

Revenue

Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing

CMS

Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT

Customer

Adoption, Pipeline Development and Commercial Expansion Advanced Across U.S. and International Markets

Company

Remains Focused on Delivering Strong Second Half Performance

BOCA

RATON, Fla., August 13, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing

highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results

and business highlights for the three months ended June 30, 2026.

Highlights

included:

● Revenues

of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from

the 2025 quarter. The decrease was driven by a lower number of units sold in the 2026

quarter, resulting in part from the inability to record the sale of eight units in Q2

due to financing approval timing. This sale will be recognized in Q3.

● Customer

adoption accelerated through expanding engagement with independent practices, larger

physician groups, and health systems.

● Sales

pipeline strengthened following CPT code implementation, supported by increasing physician

education, inbound customer inquiries and commercial activity.

● CMS

proposed a 26% increase in the hospital-based SRT delivery code, which, if finalized,

would further improve provider economics and support expanded adoption of SRT across

hospital and health system settings.

● International

commercial activity expanded across key Asia-Pacific markets, including Australia and

New Zealand, supporting future growth opportunities.

● Active

website users increased 153% year-over-year.

● Company

remains committed to delivering strong performance during the second half of 2026.

Management

Commentary

“While

our reported second quarter revenue was impacted by the timing of financing approvals for eight units, our commercial execution

remained strong throughout the quarter. Those units have since been sold and related revenue will be recognized in Q3. The delayed

financing approval affected the timing of revenue recognition, not customer demand or commercial execution,” said Joseph

Sardano, Chairman and Chief Executive Officer.

“Importantly,

we are seeing the benefits of the dedicated CPT codes reflected in growing physician engagement, expanding customer interest,

and a strengthening sales pipeline. During the quarter, we broadened relationships with larger physician groups, increased utilization

under our Fair Deal Agreement program, and advanced our commercial initiatives in both the U.S. and internationally. In addition,

we were particularly encouraged by the level of engagement we experienced across key Asia-Pacific markets, including Australia

and New Zealand, where growing awareness of SRT is creating attractive long-term opportunities.

“We

entered the third quarter with a healthy pipeline, growing customer engagement, and increasing commercial activity across both

our domestic and international markets. We remain encouraged by the momentum we are seeing across the business and focused on

executing against our five strategic priorities for 2026 - education and training, accelerating customer adoption, expanding recurring

revenue, broadening our commercial reach, and driving Sensus toward profitability,” concluded Sardano.

Second

Quarter 2026 Financial Results

Revenues

were $2.3 million for the three months ended June 30, 2026, compared to $7.3 million for the three months ended June 30, 2025,

a decrease of $5.0 million, or 68.5%. The decrease in revenue was primarily driven by a lower number of units sold (11 in the

three months ended June 30, 2026, including Fair Deal Agreements and rentals, compared to 19 in the three months ended June 30,

2025), reflecting no sales in the current period to a historically large customer. In addition, some systems placed during the

quarter were under the Fair Deal Agreement program and rental arrangements, for which revenue is recognized over the term of the

agreement rather than at the time of shipment.

Cost

of sales was $1.5 million for the three months ended June 30, 2026, compared to $4.4 million for the three months ended June 30,

2025, a decrease of $2.9 million, or 65.9%. The decrease in cost of sales was primarily related to the lower number of units sold.

Gross

profit was $0.8 million for the three months ended June 30, 2026, compared to $2.9 million for the three months ended June 30,

2025, a decrease of $2.1 million, or 72.4%. Our overall gross profit percentage was 34.8% in the three months ended June 30, 2026,

compared to 39.7% in the corresponding period in 2025. The decrease in gross profit and margin was primarily driven by product

mix, including a higher proportion of international shipments, which carry lower average selling prices, and costs associated

with new system placements pursuant to the Fair Deal Agreements, which are recognized upfront while related revenue is recognized

over the term of the agreement.

General

and administrative expense was $1.8 million for the three months ended June 30, 2026, compared to $2.0 million for the three months

ended June 30, 2025, a decrease of $0.2 million, or 10.0%. The net decrease in general and administrative expense was primarily

due to lower compensation costs, slightly offset by increases in professional fees.

Selling

and marketing expense was $1.1 million for the three months ended June 30, 2026, compared to $1.4 million for the three months

ended June 30, 2025, a decrease of $0.3 million, or 21.4%. The decrease was primarily driven by a decrease in tradeshow expenses,

commission expenses, and clinical research costs.

Research

and development expense was $1.1 million for the three months ended June 30, 2026, compared to $1.5 million for the three months

ended June 30, 2025, a decrease of $0.4 million, or 26.7%. The decrease was primarily due to a decrease in product development

costs related to next-generation systems and reduced headcount.

Other

income of $0.1 million and $0.2 million for the three months ended June 30, 2026 and 2025, respectively, relates primarily to

interest income.

The

tax expense for the second quarter of 2026 includes a $5.7 valuation allowance against net deferred tax assets.

Net

loss was $8.7 million, or $0.53 per share, compared with net loss of $1.0 million, or $0.06 per share, for the three months ended

June 30, 2025.

Adjusted

EBITDA for the second quarter of 2026 was negative $3 million, compared with negative $1.8 million for the second quarter of 2025.

Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation

expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial

measures are provided.

Cash,

restricted cash and cash equivalents were $15.2 million as of June 30, 2026, compared with $18.3 million as of March 31, 2026.

The Company had no outstanding borrowings under its revolving line of credit at June 30, 2026. Prepaid inventory was $0.6 million

as of June 30, 2026, compared with $2.5 million as of March 31, 2026. Inventories were $18.5 million as of June 30, 2026, compared

with $16.5 million as of March 31, 2026.

Conference

Call and Webcast

Sensus

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management

will discuss these financial results, provide a business update and answer questions.

Participants

are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass

the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register

can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask

the operator to be connected to the Sensus Healthcare conference call.

The

call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s

website at www.sensushealthcare.com.

Use

of Non-GAAP Financial Information

This

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management understands that investors and analysts use Adjusted

EBITDA, a non-GAAP financial measure, in analyzing the Company’s performance. Adjusted EBITDA should not be considered a

substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with

GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ

from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists

investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure

underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the

schedule below.

GAAP

TO NON-GAAP RECONCILIATION

(unaudited)

For

the Three Months Ended

June 30,

For

the Six Months Ended

June

30,

(in

thousands)

2026

2025

2026

2025

Net

loss, as reported

$ (8,749 )

$ (1,037 )

$ (11,375 )

$ (3,609 )

Add:

Depreciation

182

185

Stock

compensation expense

140

146

Income

tax expense (benefit)

5,686

(723 )

4,079

(613 )

Interest

income, net

(117 )

(183 )

(241 )

(367 )

Adjusted

EBITDA, non GAAP

$ (3,024 )

$ (1,777 )

$ (7,215 )

$ (4,258 )

About

Sensus Healthcare

Sensus

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly

effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare

offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking

Statements

This

press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements

can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,”

“expects,” “plans,” “intends,” “may,” “could,” “might,”

“will,” “should,” “approximately,” or “potential,” or negative or other variations

of those terms or comparable terminology, although not all forward-looking statements contain these words.

Forward-looking

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare,

Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer

or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances

are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments

in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press

release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial

condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking

statements contained in this press release as a result of the following factors, among others: the level and availability of government

and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers

to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including

the concentration of sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies

that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our

ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other

foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental

action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations

in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s

information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue

to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and

our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described

from time to time in our filings with the Securities and Exchange Commission.

date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments

and will address them in future disclosures, if applicable.

Any

forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no

obligation to update such statements to reflect events or circumstances after the date this press release is issued, except as

may be required by applicable law.

Investor

Relations Contact

Leigh

Salvo

New

Street Investor Relations

leigh@newstreetir.com

CONSOLIDATED

STATEMENTS OF OPERATIONS

For

the Three Months Ended

June

30,

For

the Six Months Ended

June

30,

(in

thousands, except share and per share data)

2026

2025

2026

2025

(unaudited)

Revenues

$ 2,290

$ 7,315

$ 5,684

$ 15,659

Cost

of sales

1,521

4,412

3,924

8,403

Gross

profit

769

2,903

1,760

7,256

Operating

expenses:

General and administrative

1,786

1,986

3,827

4,193

Selling and marketing

1,054

1,389

2,771

3,575

Research

and development

1,109

1,471

2,699

4,077

Total

operating expenses

3,949

4,846

9,297

11,845

Loss

from operations

(3,180 )

(1,943 )

(7,537 )

(4,589 )

Other

income:

Interest

income, net

117

183

241

367

Other

income, net

117

183

241

367

Loss

before income tax

(3,063 )

(1,760 )

(7,296 )

(4,222 )

Provision

for (benefit from) income taxes

5,686

(723 )

4,079

(613 )

Net

loss

$ (8,749 )

$ (1,037 )

$ (11,375 )

$ (3,609 )

Net

loss per share - basic

$ (0.53 )

$ (0.06 )

$ (0.69 )

$ (0.22 )

diluted

$ (0.53 )

$ (0.06 )

$ (0.69 )

$ (0.22 )

Weighted

average number of shares used in computing

net

loss per share - basic

16,462,059

16,320,036

16,462,355

16,330,891

diluted

16,462,059

16,320,036

16,462,355

16,330,891

CONSOLIDATED

BALANCE SHEETS

(in

thousands, except shares and per share data)

of June 30,

2026

As of December 31,

2025

(unaudited)

Assets

Current assets

Cash, restricted cash and

cash equivalents

$ 15,186

$ 22,083

Accounts receivable, net

1,680

6,041

Inventories

18,459

14,563

Prepaid inventory

607

1,522

Other current assets

1,745

1,683

Total current assets

37,677

45,892

Property and equipment, net

2,748

1,976

Deferred tax asset

—

4,079

Operating lease right-of-use assets,

net

329

452

Other noncurrent

assets

505

640

Total

assets

$ 41,259

$ 53,039

Liabilities

and stockholders’ equity Current liabilities

Accounts

payable and accrued expenses

$ 3,167

$ 3,343

Product warranties

267

275

Operating lease liabilities, current

portion

274

262

Deferred revenue,

current portion

619

842

Total current Liabilities

4,327

4,722

Operating lease liabilities, net of

current portion

209

Deferred revenue,

net of current portion

—

Total

liabilities

4,396

4,941

Commitments

and contingencies Stockholders’ equity

Preferred stock, 5,000,000 shares authorized

and none issued and outstanding

—

Common stock, $0.01 par value -

50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at June 30, 2026; 17,056,845 issued and 16,463,809 outstanding at December

31, 2025

169

Additional paid-in capital

46,230

46,090

Treasury stock, 593,036 shares at cost,

at June 30, 2026 and December 31, 2025

(3,876 )

(Accumulated deficit)

retained earnings

(5,660 )

5,715

Total

stockholders’ equity

36,863

48,098

Total

liabilities and stockholders’ equity

$ 41,259

$ 53,039

GRAPHIC

Filename: img001_v1.jpg · Sequence: 3

Binary file (7866 bytes)

Download img001_v1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 13, 2026

Entity File Number

001-37714

Entity Registrant Name

SENSUS

HEALTHCARE, INC.

Entity Central Index Key

0001494891

Entity Tax Identification Number

27-1647271

Entity Incorporation, State or Country Code

Entity Address, Address Line One

851

Broken Sound Pkwy.

Entity Address, Address Line Two

NW # 215

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33487

City Area Code

(561)

Local Phone Number

922-5808

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

SRTS

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration